Johnson & Johnson reported topline Phase III data showing that the dual bispecific regimen of teclistamab (Tecvayli) and talquetamab (Talvey) reduced the risk of disease progression or death by 89% versus standard therapy in relapsed or refractory multiple myeloma. The HR of 0.11 is the lowest reported for a Phase III bispecific antibody study in this setting and could further shift these agents into earlier lines of treatment.
The MonumenTAL-6 study enrolled patients with relapsed/refractory multiple myeloma who had received one to four prior lines of therapy, including lenalidomide and an anti-CD38 antibody. The study evaluated teclistamab plus talquetamab against investigator's choice of standard combination therapy. Teclistamab targets BCMA while talquetamab targets GPRC5D, allowing the combination to attack myeloma cells through two independent antigens. The strategy is intended to reduce antigen escape, a recognized mechanism of resistance following BCMA-directed therapy.
Both experimental arms met the trial's primary endpoint of progression-free survival, with statistically significant and clinically meaningful improvements over standard of care. The teclistamab-talquetamab combination delivered the larger effect: an 89% reduction in the risk of progression or death (HR 0.11; 95% CI, 0.08-0.16) and a 62% reduction in the risk of death (HR 0.38). Full efficacy data for the talquetamab-pomalidomide arm were not disclosed in the topline release. Safety for both combination arms was described as consistent with the known profiles of each drug used alone, and the Independent Data Monitoring Committee recommended unblinding the study early, at the first interim analysis, based on the strength of the results.
Both bispecifics are already FDA-approved for heavily pretreated multiple myeloma, while teclistamab recently expanded into earlier-line treatment in combination with daratumumab. MonumenTAL-6 pushes the dual-bispecific strategy further into second-line disease. MonumenTAL-6 is the fifth positive Phase III study supporting J&J's earlier-line multiple myeloma strategy and further expands evidence for its BCMA- and GPRC5D-targeted immunotherapy portfolio.